Literature DB >> 21143558

Bone density and health-related quality of life in adult patients with severe haemophilia.

M Khawaji1, J Astermark, S Von Mackensen, K Akesson, E Berntorp.   

Abstract

Severe haemophilia and reduced bone density can negatively influence perception of patient's health-related quality of life (HRQoL), especially considering future aspects, the risk of losing independence or pain suffering. The aim of this study was to assess levels of HRQoL in severe haemophilia patients and to compare HRQoL to those of the general population as well as to determine whether reduced bone density is correlated to the perceived HRQoL. Patients were divided into two groups based on timing of being treated with prophylaxis: Group A (started prophylaxis at age of ≤ 3 years; n = 22); Group B (at age of >3 years; n = 15). The bone mineral density (BMD g cm(-2)) of different measured sites was measured by dual energy X-ray absorptiometry (DXA). HRQoL was assessed using SF-36 questionnaire. Group A have mean BMD T-score >-1.0 (i.e. normal score) at all measured sites, and have almost similar scores in the SF-36 domains compared with the reference population. Group B have mean BMD T-score <-1.0 at hip region, and >-1.0 at lumbar spine and total body, and their scores in the SF-36 domains were lower compared with the reference population. Moreover, significant correlations were found between BMD at femoral neck and total body with physical domains. With adequate long-term prophylaxis since early childhood, adult patients with haemophilia report a comparable BMD and HRQoL to the Swedish reference population. Reduced BMD in group B correlated with impaired physical health, which underscores the importance of early onset of adequate prophylactic treatment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21143558     DOI: 10.1111/j.1365-2516.2010.02423.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  8 in total

1.  Impact of mild versus moderate intensity aerobic walking exercise training on markers of bone metabolism and hand grip strength in moderate hemophilic A patients.

Authors:  Fadwa Al-Ghalib Al-Sharif; Osama Hussien Al-Jiffri; Shehab Mahmoud Abd El-Kader; Eman Mohamed Ashmawy
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

Review 2.  Haemophilia and joint disease: pathophysiology, evaluation, and management.

Authors:  Karin Knobe; Erik Berntorp
Journal:  J Comorb       Date:  2011-12-27

3.  Effect of whole body vibration training on quadriceps strength, bone mineral density, and functional capacity in children with hemophilia: a randomized clinical trial.

Authors:  S El-Shamy
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-06-01       Impact factor: 2.041

Review 4.  Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia.

Authors:  Nihal Bakeer; Amy D Shapiro
Journal:  F1000Res       Date:  2019-07-09

5.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 6.  Low Bone Mineral Density in Hemophiliacs.

Authors:  Jennifer Gebetsberger; Michael Schirmer; Walter J Wurzer; Werner Streif
Journal:  Front Med (Lausanne)       Date:  2022-02-02

7.  Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia.

Authors:  Leila Valizadeh; Fahimeh Alsadat Hosseini; Vahid Zamanzadeh; Fatemeh Heidarnezhad; Madineh Jasemi; Kamran Bagheri Lankarani
Journal:  Indian J Palliat Care       Date:  2015 Sep-Dec

8.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.